E-submission
Search
- Page Path
- HOME > Search
Original Article
- Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
- Yoon Jung Hwang, Youngeun Lee, Hyunjin Park, Yangkyu Lee, Kyoungbun Lee, Haeryoung Kim
- J Pathol Transl Med. 2021;55(5):338-348. Published online September 2, 2021
- DOI: https://doi.org/10.4132/jptm.2021.07.26
- 3,156 View
- 110 Download
- 4 Web of Science
- 4 Crossref
-
Abstract
PDF
Supplementary Material - Background
Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).
Methods
A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.
Results
As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.
Conclusions
Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT. -
Citations
Citations to this article as recorded by
- Measures for response assessment in HCC treatment
Fereshteh Yazdanpanah, Omar Al-Daoud, Moein Moradpour, Stephen Hunt
Hepatoma Research.2024;[Epub] CrossRef - Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model
Lujun Shen, Yiquan Jiang, Tao Zhang, Fei Cao, Liangru Ke, Chen Li, Gulijiayina Nuerhashi, Wang Li, Peihong Wu, Chaofeng Li, Qi Zeng, Weijun Fan
Cancer Informatics.2024;[Epub] CrossRef - Construction and validation of a novel signature based on epithelial-mesenchymal transition–related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment
Biao Gao, Yafei Wang, Shichun Lu
Functional & Integrative Genomics.2023;[Epub] CrossRef - Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma
Biao Gao, Yafei Wang, Shichun Lu
Scientific Reports.2023;[Epub] CrossRef
- Measures for response assessment in HCC treatment
Review
- Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
- Cheol Keun Park, Woo-Hee Jung, Ja Seung Koo
- J Pathol Transl Med. 2016;50(3):173-180. Published online April 11, 2016
- DOI: https://doi.org/10.4132/jptm.2016.02.02
- 13,711 View
- 477 Download
- 32 Web of Science
- 30 Crossref
-
Abstract
PDF
- Breast cancer, one of the most common cancers in women, has various treatment modalities. Neoadjuvant therapy (NAT) has been used in many clinical trials because it is easy to evaluate the treatment response to therapeutic agents in a short time period; consequently, NAT is currently a standard treatment modality for large-sized and locally advanced breast cancers, and its use in early-stage breast cancer is becoming more common. Thus, chances to encounter breast tissue from patients treated with NAT is increasing. However, systems for handling and evaluating such specimens have not been established. Several evaluation systems emphasize a multidisciplinary approach to increase the accuracy of breast cancer assessment. Thus, detailed and systematic evaluation of clinical, radiologic, and pathologic findings is important. In this review, we compare the major problems of each evaluation system and discuss important points for handling and evaluating NAT-treated breast specimens.
-
Citations
Citations to this article as recorded by- Good practice: The experiences with the utilization of residual cancer burden—A single institution study
Anita Sejben, Fanni Hegedűs, Szintia Almási, Márton Berta, Orsolya Oláh‐Németh, Tamás Zombori
Thoracic Cancer.2023; 14(11): 963. CrossRef - Assessing the Correlation of Rate of Pathological Complete Response and Outcome in Post Neoadjuvant Chemotherapy Setting and Molecular Subtypes of Breast Cancer
Ahmad Omair, Abdulmohsen Alkushi, Ghaida Alamri, Talal Almojel, Sara Alsadun, Emad Masuadi, Haitham Arabi, Amin E Mohamed, Omalkhair A Abulkhair
Cureus.2023;[Epub] CrossRef - Compression OCT-elastography combined with speckle-contrast analysis as an approach to the morphological assessment of breast cancer tissue
Anton A. Plekhanov, Ekaterina V. Gubarkova, Marina A. Sirotkina, Alexander A. Sovetsky, Dmitry A. Vorontsov, Lev A. Matveev, Sergey S. Kuznetsov, Alexandra Y. Bogomolova, Alexey Y. Vorontsov, Alexander L. Matveyev, Sergey V. Gamayunov, Elena V. Zagaynova,
Biomedical Optics Express.2023; 14(6): 3037. CrossRef - Ambiguity-aware breast tumor cellularity estimation via self-ensemble label distribution learning
Xiangyu Li, Xinjie Liang, Gongning Luo, Wei Wang, Kuanquan Wang, Shuo Li
Medical Image Analysis.2023; 90: 102944. CrossRef - Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer
Maryam Nemati Shafaee, Shalini Makawita, Bora Lim, Matthew J Ellis, Michelle S Ludwig
Clinical Breast Cancer.2022; 22(4): e536. CrossRef - Pathology after neoadjuvant treatment – How to assess residual disease
Giuseppe Viale, Nicola Fusco
The Breast.2022; 62: S25. CrossRef - Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
Yongguang Liu, Mingxiang Wu, Wenyong Tan, Jingshan Gong, Jie Ma, Mohammad Farukh Hashmi
Contrast Media & Molecular Imaging.2022;[Epub] CrossRef - Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study
Weronika Bulska-Będkowska, Paulina Czajka-Francuz, Sylwia Cisoń-Jurek, Aleksander J. Owczarek, Tomasz Francuz, Jerzy Chudek
Journal of Interferon & Cytokine Research.2022; 42(11): 557. CrossRef - The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
Jinzhao Liu, Yifei Li, Weifang Zhang, Chenhui Yang, Chao Yang, Liang Chen, Mingjian Ding, Liang Zhang, Xiaojun Liu, Guozhong Cui, Yunjiang Liu
Frontiers in Surgery.2022;[Epub] CrossRef - The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy
Lorena Alexandra Lisencu, Andrei Roman, Simona Visan, Eduard-Alexandru Bonci, Andrei Pașca, Emilia Grigorescu, Elena Mustea, Andrei Cismaru, Alexandru Irimie, Cosmin Lisencu, Loredana Balacescu, Ovidiu Balacescu, Oana Tudoran
Medicina.2022; 58(10): 1494. CrossRef - Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
Elisa Agostinetto, Flavia Jacobs, Véronique Debien, Alex De Caluwé, Catalin-Florin Pop, Xavier Catteau, Philippe Aftimos, Evandro de Azambuja, Laurence Buisseret
Cancers.2022; 14(21): 5467. CrossRef - Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Joshua J. Li, Julia Y. Tsang, Gary M. Tse
Cancers.2021; 13(16): 4233. CrossRef - SPIE-AAPM-NCI BreastPathQ challenge: an image analysis challenge for quantitative tumor cellularity assessment in breast cancer histology images following neoadjuvant treatment
Nicholas Petrick, Shazia Akbar, Kenny H. Cha, Sharon Nofech-Mozes, Berkman Sahiner, Marios A. Gavrielides, Jayashree Kalpathy-Cramer, Karen Drukker, Anne L. Martel, for the BreastPathQ Challenge Group
Journal of Medical Imaging.2021;[Epub] CrossRef - Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography
Ryusuke Murakami, Hitomi Tani, Shinichiro Kumita, Nachiko Uchiyama
Acta Radiologica Open.2021;[Epub] CrossRef - Los márgenes
Laia Bernet, María Angeles Montero Fernández
Revista de Senología y Patología Mamaria.2021; 34: S25. CrossRef - Neoadjuvant chemotherapy in non‐metastatic breast cancer: a study on practice trends in a regional cancer treatment service
Edmond Ang, Navin Wewala, Rebecca Carroll, Garry Forgeson, Malcolm Anderson, Jennifer Fernando, Jody Jordan, Richard Isaacs
Internal Medicine Journal.2020; 50(3): 315. CrossRef - Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy
Anita Sejben, Renáta Kószó, Zsuzsanna Kahán, Gábor Cserni, Tamás Zombori
Pathology & Oncology Research.2020; 26(4): 2747. CrossRef - Integrating evolutionary dynamics into cancer therapy
Robert A. Gatenby, Joel S. Brown
Nature Reviews Clinical Oncology.2020; 17(11): 675. CrossRef - Assessing the accuracy of conventional gadolinium‐enhanced breast MRI in measuring the nodal response to neoadjuvant chemotherapy (NAC) in breast cancer
Lisa Christine Murphy, Edel Marie Quinn, Zeeshan Razzaq, Claire Brady, Vicki Livingstone, Lorna Duddy, Josephine Barry, Henry Paul Redmond, Mark Anthony Corrigan
The Breast Journal.2020; 26(11): 2151. CrossRef - Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning
Joon Ho Choi, Hyun-Ah Kim, Wook Kim, Ilhan Lim, Inki Lee, Byung Hyun Byun, Woo Chul Noh, Min-Ki Seong, Seung-Sook Lee, Byung Il Kim, Chang Woon Choi, Sang Moo Lim, Sang-Keun Woo
Scientific Reports.2020;[Epub] CrossRef - Patterns of Regression in Breast Cancer after Primary Systemic Treatment
Tamás Zombori, Gábor Cserni
Pathology & Oncology Research.2019; 25(3): 1153. CrossRef - The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer
Hee Yeon Kim, Tae Hyun Kim, Hye Kyoung Yoon, Anbok Lee
Journal of Breast Cancer.2019; 22(3): 425. CrossRef - Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)—A concordance comparison cohort analysis
Wen-Pei Wu, Hwa-Koon Wu, Chih-Jung Chen, Chih-Wie Lee, Shou-Tung Chen, Dar-Ren Chen, Chen-Te Chou, Chi Wei Mok, Hung-Wen Lai, Pascal A. T. Baltzer
PLOS ONE.2019; 14(10): e0222917. CrossRef - Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model
Marion M. Deken, Desirée L. Bos, Willemieke S. F. J. Tummers, Taryn L. March, Cornelis J. H. van de Velde, Mark Rijpkema, Alexander L. Vahrmeijer
EJNMMI Research.2019;[Epub] CrossRef - Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer
Ida Skarping, Daniel Förnvik, Hanna Sartor, Uffe Heide-Jørgensen, Sophia Zackrisson, Signe Borgquist
BMC Cancer.2019;[Epub] CrossRef - ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer
Anbok Lee, Kyu Yeoun Won, Sung-Jig Lim, Sun Young Cho, Sang-Ah Han, SaeGwang Park, Jeong-Yoon Song
Pathology - Research and Practice.2018; 214(5): 619. CrossRef - Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer
Yunju Kim, Sung Hun Kim, Byung Joo Song, Bong Joo Kang, Kwang-il Yim, Ahwon Lee, Yoonho Nam
Korean Journal of Radiology.2018; 19(4): 682. CrossRef - Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database
Matthew MacLean, Xin Luo, Shidan Wang, Kemp Kernstine, David E. Gerber, Yang Xie
Oncotarget.2018; 9(36): 24470. CrossRef - Automatic cellularity assessment from post‐treated breast surgical specimens
Mohammad Peikari, Sherine Salama, Sharon Nofech‐Mozes, Anne L. Martel
Cytometry Part A.2017; 91(11): 1078. CrossRef - The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case
Jingxian Ding, Pinghua Hu, Jun Chen, Xiaobo Wu, Yali Cao
Oncoscience.2016; 3(9-10): 268. CrossRef
- Good practice: The experiences with the utilization of residual cancer burden—A single institution study
Original Article
- Changes in Protein Expression in Breast Cancer after Anthracycline-Based Chemotherapy.
- Ho chang Lee, Jae Ok Lee, In Ae Park
- Korean J Pathol. 2007;41(3):165-170.
- 1,885 View
- 22 Download
-
Abstract
PDF
- Background
: Anthracyclines are the standard agents used to treat patients with advanced breast carcinoma. Some molecules are reportedly associated with anthracycline resistance; however, there has been some controversy surrounding these claims. The gain or loss of certain molecules after chemotherapy can explain the discrepancies in the results.
Methods
: We evaluated the expression levels of the estrogen receptor (ER), p53, and bcl-2 in specimens obtained from twenty patients with advanced breast cancer before and after anthracyclinebased chemotherapy using immunohistochemistry (IHC). We also examined HER2/neu expression in these specimens using IHC and fluorescence in situ hybridization (FISH) analysis.
Results
: After chemotherapy, one of the twenty cases (5%) showed decreased ER expression, one (5%) showed decreased p53 expression, and one (5%) showed increased bcl-2 expression. IHC and FISH analysis in pre- and post-chemotherapy specimens showed that the expression of HER2/neu changed from equivocal to negative in one case (5%).
Conclusion
: Our results showed that the expression levels of HER2/neu, ER, p53 and bcl-2 remained stable after chemotherapy, although the statistical significance of these results may not be validated due to the small number of cases. We also suggested that the resistance to anthracycline-based chemotherapy might not be associated with the modification of these molecules.
First
Prev
